Literature DB >> 24009090

Effectiveness of screening for amblyopia and other eye disorders in a prospective birth cohort study.

Harry J de Koning1, Johanna H Groenewoud, V Kathleen Lantau, A M Tjiam, W Christina Hoogeveen, Jan Tjeerd H N de Faber, Rikard E Juttmann, Huibert J Simonsz.   

Abstract

OBJECTIVE: To establish whether the current vision screening practice in the Netherlands is effective in preventing permanent visual loss and to estimate the sensitivity of the programme. SETTINGS: In the Netherlands, all children are invited for preverbal (1, 3, 6-9 and 14-24 months) and preschool (36, 45, and 60-72 months) vision screening. Screening attendance is high, but the effectiveness in reducing amblyopia is unknown.
METHODS: In a 7-year cohort study, 4624 children born in the city of Rotterdam between 16 September 1996 and 15 May 1997 were followed through all routine vision screening examinations. At age seven, visual acuity (VA) of children still living in Rotterdam was assessed by study orthoptists. In case of VA > 0.1 logMAR in one or both eyes, two or more logMAR lines of interocular difference or eye disorders like strabismus, children underwent a more intensive eye examination.
RESULTS: Attendance at the 9-month screening was 89%, decreasing to about 75% at later examinations. Of preverbal tests, 2.5% were positive, and of preschool tests, 10%. In total, 19% of children had a positive vision screening test at least once. Amblyopia prevalence was 3.4%. Sensitivity of the vision screening programme was 73% and specificity 83%. At age seven, 0.7-1.2% (confirmed vs final exam) of the children had a VA > 0.3 logMAR in the worse eye compared with 2-3.9% (in literature) reported prevalence in non-screening situations. Children who were less frequently screened had a higher chance of poor vision (>0.3 logMAR) at age seven.
CONCLUSION: The Dutch child vision screening programme may reduce the risk of persistent amblyopia (VA > 0.3 logMAR) at age seven by more than half.

Entities:  

Mesh:

Year:  2013        PMID: 24009090     DOI: 10.1177/0969141313497355

Source DB:  PubMed          Journal:  J Med Screen        ISSN: 0969-1413            Impact factor:   2.136


  6 in total

1.  The Global Prevalence of Amblyopia in Children: A Systematic Review and Meta-Analysis.

Authors:  Budan Hu; Zongshun Liu; Jiao Zhao; Li Zeng; Gengsheng Hao; Dan Shui; Ke Mao
Journal:  Front Pediatr       Date:  2022-05-04       Impact factor: 3.569

2.  Recommendation for ophthalmic care in German preschool health examination and its adherence: Results of the prospective cohort study ikidS.

Authors:  Alexander K Schuster; Heike M Elflein; Christiane Diefenbach; Christine Gräf; Jochem König; Martina F Schmidt; Kathleen Schnick-Vollmer; Michael S Urschitz
Journal:  PLoS One       Date:  2018-12-03       Impact factor: 3.240

Review 3.  Comparison of the pediatric vision screening program in 18 countries across five continents.

Authors:  Ai-Hong Chen; Nurul Farhana Abu Bakar; Patricia Arthur
Journal:  J Curr Ophthalmol       Date:  2019-09-03

Review 4.  Scope and costs of autorefraction and photoscreening for childhood amblyopia-a systematic narrative review in relation to the EUSCREEN project data.

Authors:  Anna M Horwood; Helen J Griffiths; Jill Carlton; Paolo Mazzone; Arinder Channa; Mandy Nordmann; Huibert J Simonsz
Journal:  Eye (Lond)       Date:  2020-11-30       Impact factor: 3.775

5.  The cost-effectiveness of different visual acuity screening strategies in three European countries: A microsimulation study.

Authors:  Eveline A M Heijnsdijk; Mirjam L Verkleij; Jill Carlton; Anna M Horwood; Maria Fronius; Jan Kik; Frea Sloot; Cristina Vladutiu; Huibert J Simonsz; Harry J de Koning
Journal:  Prev Med Rep       Date:  2022-06-27

6.  [Visual acuity in German preschool children-results of a cross-sectional study].

Authors:  Heike M Elflein; Roman Pokora; Denis Müller; Alexander K Schuster; Klaus Jahn; Katharina A Ponto; Susanne Pitz; Norbert Pfeiffer; Michael S Urschitz
Journal:  Ophthalmologe       Date:  2021-05       Impact factor: 1.059

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.